Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
186
-
Total 13F shares, excl. options
-
58.2M
-
Shares change
-
+5.04M
-
Total reported value, excl. options
-
$1.2B
-
Value change
-
-$2.92M
-
Put/Call ratio
-
0.42
-
Number of buys
-
110
-
Number of sells
-
-100
-
Price
-
$20.58
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q3 2023
274 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q3 2023.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 186 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.2M shares
of 62.7M outstanding shares and own 92.87% of the company stock.
Largest 10 shareholders include FMR LLC (7.7M shares), WELLINGTON MANAGEMENT GROUP LLP (6.57M shares), VANGUARD GROUP INC (5.21M shares), RTW INVESTMENTS, LP (5.15M shares), STATE STREET CORP (4.38M shares), BlackRock Inc. (4.22M shares), Bellevue Group AG (3.51M shares), JPMORGAN CHASE & CO (1.67M shares), DIMENSIONAL FUND ADVISORS LP (1.33M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.11M shares).
This table shows the top 186 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.